First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
The pilot plant is focused on scaling up beverage production and will support applications
Pharma Solutions operates 10 research and development and/or production sites globally
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
The validations confirm the completion of the applications and commence the scientific review process
The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
The agreement sets terms under which POC will manufacture the product or receive royalties
Subscribe To Our Newsletter & Stay Updated
